biote Corp. (BTMD)
Trains doctors to treat hormone imbalances using pellet therapy and provides their practice software.
$2.24-0.04%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago-42.4%
The outlook
BTMD is trading near the lower end of its 52-week range at $2.24, with analyst consensus showing Strong Buy ratings and an average price target about 22% above the current level. The stock sits mixed relative to its moving averages, reflecting some near-term uncertainty despite the broader bullish lean from coverage.
What’s behind the score
Analyst consensusStrong Buy — 1.5 avg of 4 analysts
Price trendMixed vs its moving averages
52-week range28% of the way from its 52-week low to high
Price targetAvg target +22% vs current price
Analyst price target
~12-month · 4 analysts$2.73average target+22.0% vs now
Now $2.24
Low $2.00High $3.43
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$79.6M
52-wk high
$4.75
52-wk low
$1.27
50-day avg
$2.18
200-day avg
$2.26
Trailing P/E
5.2